Eli Lilly & Co. closed $177.18 short of its 52-week high ($972.53), which the company reached on August 22nd. Supported by ...

After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion ...

Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

The Endowment made the grants through the latest round of its Religion and Cultural Institutions Initiative, a national initiative launched in 2019 that is supporting efforts to improve the public ...

The Biden administration is proposing a rule that would require the U.S. government to cover weight-loss drugs, potentially expanding access for millions of Americans with obesity and creating ...